Nov 09, 2009 Press Release for Alnylam
Alnylam to Webcast R&D Day on Thursday, November 12, 2009
Nov 09, 2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2009--
Alnylam scientists and management will review and provide updates on Alnylam platform advancements, delivery strategies, and pipeline of novel RNAi therapeutics. In addition, Alnylam will host two guest speakers:
- Professor
Allan R. Glanville , Director of Thoracic Medicine and Medical Director Lung Transplantation, St. Vincent’s Hospital,Sydney , will discuss respiratory syncytial virus (RSV) infection in the lung transplant patient population; and, -
Professor
Philip N. Hawkins , National Amyloidosis Centre, Division of Medicine, and University College London Medical SchoolRoyal Free Hospital, will discuss transthyretin (TTR)-mediated amyloidosis.
Alnylam’s R&D Day will be held on
About
Alnylam is a biopharmaceutical company developing novel therapeutics
based on RNA interference, or RNAi. The company is applying its
therapeutic expertise in RNAi to address significant medical needs, many
of which cannot effectively be addressed with small molecules or
antibodies, the current major classes of drugs. Alnylam is leading the
translation of RNAi as a new class of innovative medicines with
peer-reviewed research efforts published in the world’s top scientific
journals including Nature, Nature Medicine, and Cell.
The company is leveraging these capabilities to build a broad pipeline
of RNAi therapeutics; its most advanced program is in Phase II human
clinical trials for the treatment of respiratory syncytial virus (RSV)
infection and is partnered with Cubist and
Source:
Alnylam Pharmaceuticals, Inc.
Cynthia Clayton (Investors)
617-551-8207
or
Kathryn
Morris (Media)
Yates Public Relations
845-635-9828